Email this article Expression of the phosphorylated variant of the AKT1-kinase (p-AKT1) in well-differentiated pancreatic neuroendocrine tumors: immunohistochemical evaluation
- Authors: Delektorskaya V.V.1, Solov'eva O.N.1, Chemeris G.Y.1, Patyutko Y.I.1
-
Affiliations:
- N.N. Blokhin National Medical Research Centre of Oncology
- Issue: Vol 46, No 4 (2018)
- Pages: 314-322
- Section: ARTICLES
- URL: https://almclinmed.ru/jour/article/view/849
- DOI: https://doi.org/10.18786/2072-0505-2018-46-4-314-322
- ID: 849
Cite item
Full Text
Abstract
Background: Well-differentiated pancreatic neuroendocrine tumors (pNETs) represent a group of rare epithelial neoplasms with a highly variable clinical course. AKT1 is one of the most frequently activated protein kinases in pNETs, which promotes the tumor growth and is of interest as a prognostic factor and a target for new treatment approaches.
Aim: To study the expression of the phosphorylated variant of AKT1-kinase (p-AKT1) in primary pNETs and their liver metastases and to correlate the results with various clinical and pathological parameters and the disease prognosis.
Materials and methods: P-AKT1 expression was studied by the immunohistochemical analysis of the primary lesions and liver metastases in 52 pNETs patients.
Results: A high level of cytoplasmic and/or nuclear immunoreactivity was detected in 24/52 of the primary pNETs (46.2%) and in 16/27 of their liver metastases (59.3%). p-AKT1 expression was observed in 3 (21.4%) of NET grade (G) 1, in 14 (46.7%) of NET G2, and in 7 (87.5%) of NET G3. p-AKT1 expression was more frequently identified in pNET G3 category and increased during the tumor progression in metachronous liver metastases, as compared to the corresponding primary tumor. In addition, p-AKT1 positivity was significantly associated with an increase of grade from G1 to G3 (p = 0.004), the Ki-67 index (p = 0.029), the pTNM stage (p = 0.0008), perineural invasion (p = 0.031) and a decrease in disease-free survival (p = 0.05).
Conclusion: The results suggest that p-АКТ1 plays an important role in the pathogenesis of pNETs and may be an additional criterion for assessment of the prognosis and treatment effectiveness in this type of tumors.
Keywords
About the authors
V. V. Delektorskaya
N.N. Blokhin National Medical Research Centre of Oncology
Author for correspondence.
Email: delektorskaya@yandex.ru
Vera V. Delektorskaya – MD, PhD, Head of Histochemistry and Electron Microscopy Laboratory, Department of Pathology of Human Tumors
24 Kashirskoe shosse, Moscow, 115478
РоссияO. N. Solov'eva
N.N. Blokhin National Medical Research Centre of Oncology
Email: fake@neicon.ru
Olesya N. Solov'eva – MD, Postgraduate Student, Department of Liver and Рancreatic Tumors
24 Kashirskoe shosse, Moscow, 115478
РоссияG. Yu. Chemeris
N.N. Blokhin National Medical Research Centre of Oncology
Email: fake@neicon.ru
Galina Yu. Chemeris – PhD (in Biology), Senior Research Fellow, Department of Pathology of Human Tumors
24 Kashirskoe shosse, Moscow, 115478
РоссияYu. I. Patyutko
N.N. Blokhin National Medical Research Centre of Oncology
Email: fake@neicon.ru
Yuri I. Patyutko – MD, PhD, Professor, Chief Research Fellow, Department of Liver and Рancreatic Tumors
24 Kashirskoe shosse, Moscow, 115478
РоссияReferences
- Ohmoto A, Rokutan H, Yachida S. Pancreatic neuroendocrine neoplasms: basic biology, current treatment strategies and prospects for the future. Int J Mol Sci. 2017;18(1). pii: E143. doi: 10.3390/ijms18010143.
- Simtniece Z, Vanags A, Strumfa I, Sperga M, Vasko E, Prieditis P, Trapencieris P, Gardovskis J. Morphological and immunohistochemical profile of pancreatic neuroendocrine neoplasms. Pol J Pathol. 2015;66(2): 176–94. doi: 10.5114/pjp.2015.53015.
- Kloppel G, Couvelard A, Hruban R, Klimstra D, Komminoth P, Osamura R. Neoplasms of the neuroendocrine pancreas. Introduction. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J, editors. WHO classification of tumours of endocrine organs. Lyon: IARC; 2017. p. 211–4.
- Rinke A, Gress TM. Neuroendocrine cancer, therapeutic strategies in G3 cancers. Digestion. 2017;95(2): 109–14. doi: 10.1159/000454761.
- Robbins HL, Hague A. The PI3K/Akt Pathway in Tumors of Endocrine Tissues. Front Endocrinol (Lausanne). 2016;6:188. doi: 10.3389/fendo.2015.00188.
- Ocana A, Vera-Badillo F, Al-Mubarak M, Templeton AJ, Corrales-Sanchez V, Diez-Gonzalez L, Cuenca-Lopez MD, Seruga B, Pandiella A, Amir E. Activation of the PI3K/mTOR/ AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS One. 2014;9(4):e95219. doi: 10.1371/journal. pone.0095219.
- Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol. 2005;207(2): 139–46. doi: 10.1002/path.1829.
- Xiao L, Wang YC, Li WS, Du Y. The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res. 2009;28:152. doi: 10.1186/1756-9966-28-152.
- Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res. 2009;15(5): 1821–9. doi: 10.1158/1078-0432.CCR-08-2138.
- Oh MH, Lee HJ, Yoo SB, Xu X, Choi JS, Kim YH, Lee SY, Lee CT, Jheon S, Chung JH. Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer. Virchows Arch. 2012;460(6): 601–9. doi: 10.1007/s00428-012-1239-6.
- Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features. Oncol Rep. 2013;30(2): 623–36. doi: 10.3892/or.2013.2512.
- Yu Z, Weinberger PM, Sasaki C, Egleston BL, Speier WF 4th, Haffty B, Kowalski D, Camp R, Rimm D, Vairaktaris E, Burtness B, Psyrri A. Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(3): 553–8. doi: 10.1158/1055-9965.EPI-06-0121.
- Wu N, Du Z, Zhu Y, Song Y, Pang L, Chen Z. The expression and prognostic impact of the PI3K/ AKT/mTOR signaling pathway in advanced esophageal squamous cell carcinoma. Technol Cancer Res Treat. 2018;17:1533033818758772. doi: 10.1177/1533033818758772.
- Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. Mol Oncol. 2017;11(9): 1130–42. doi: 10.1002/1878-0261.12078.
- Komori Y, Yada K, Ohta M, Uchida H, Iwashita Y, Fukuzawa K, Kashima K, Yokoyama S, Inomata M, Kitano S. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors. J Hepatobiliary Pancreat Sci. 2014;21(4): 288–95. doi: 10.1002/ jhbp.26.
- Ali G, Boldrini L, Capodanno A, Pelliccioni S, Servadio A, Crisman G, Picchi A, Davini F, Mussi A, Fontanini G. Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. Exp Ther Med. 2011;2(5): 787–92. doi: 10.3892/etm.2011.291.
- Gagliano T, Bellio M, Gentilin E, Mole D, Tagliati F, Schiavon M, Cavallesco NG, Andriolo LG, Ambrosio MR, Rea F, Degli Uberti E, Zatelli MC. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. Endocr Relat Cancer. 2013;20(4): 463–75. doi: 10.1530/ERC-13-0042.
- Falletta S, Partelli S, Rubini C, Nann D, Doria A, Marinoni I, Polenta V, Di Pasquale C, Degli Uberti E, Perren A, Falconi M, Zatelli MC. mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016;23(11): 883–91. doi: 10.1530/ERC-16-0329.
- Pellat A, Dreyer C, Couffignal C, Walter T, LombardBohas C, Niccoli P, Seitz JF, Hentic O, Andre T, Coriat R, Faivre S, Zappa M, Ruszniewski P, Pote N, Couvelard A, Raymond E. Clinical and biomarker evaluations of sunitinib in patients with grade 3 digestive neuroendocrine neoplasms. Neuroendocrinology. 2018;107(1): 24–31. doi: 10.1159/000487237.
Supplementary files
